z-logo
Premium
Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma
Author(s) -
JACOBSEN JAN,
GRANKVIST KJELL,
RASMUSON TORGNY,
LJUNGBERG BÖRJE
Publication year - 2006
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2006.06138.x
Subject(s) - chromophobe cell , vascular endothelial growth factor , renal cell carcinoma , angiogenesis , pathology , metastasis , medicine , clear cell , kidney cancer , papillary renal cell carcinomas , vascular endothelial growth factor a , oncology , biology , cancer , vegf receptors
OBJECTIVE To investigate the protein expression of vascular endothelial growth factor (VEGF) isoforms in relation to the clinical course in patients with different renal cell carcinoma (RCC) types, as angiogenesis is essential for tumour growth and metastasis. PATIENTS AND METHODS Western blots were assayed of protein extracts from tumour and concomitant kidney cortex samples from 96 patients. The levels of VEGF 189 , VEGF 165 , and VEGF 121 isoforms were correlated with clinicopathological characteristics and survival. RESULTS VEGF 189 levels were significantly higher in kidney cortex and chromophobe RCC than in papillary and conventional RCC. In papillary RCCs, VEGF 189 levels correlated inversely with tumour stage and tumour size. VEGF 165 levels were higher in kidney cortex than in RCC, but there was no difference among the RCC types. VEGF 121 expression was associated with less advanced tumour stage in conventional RCC. Using multivariate analysis, VEGF 189 remained as an independent prognostic factor for patients with papillary RCC. CONCLUSIONS VEGF 189 was associated with tumour progression; in papillary RCC, VEGF 189 was a significant independent prognostic factor. VEGF protein isoform patterns differed among the specific RCC types. Additional knowledge is essential to design new anti‐angiogenic therapies for all RCC types.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here